AAPL327.36+0.77 (+0.23%) ▲|ABBV255.33+1.95 (+0.77%) ▲|ABT100.05-1.61 (-1.58%) ▼|ACN140.89-3.84 (-2.65%) ▼|ADBE226.71-8.03 (-3.42%) ▼|AMAT567.75+42.05 (+8.00%) ▲|AMD541.70+38.13 (+7.57%) ▲|AMGN364.49+0.32 (+0.09%) ▲|AMT163.75-3.32 (-1.98%) ▼|AMZN248.49-1.51 (-0.60%) ▼|AVGO386.17+8.01 (+2.12%) ▲|AXP351.03-0.90 (-0.26%) ▼|BA204.31-5.18 (-2.47%) ▼|BAC61.30+0.88 (+1.45%) ▲|BKNG177.97-1.48 (-0.82%) ▼|BLK1,040.96-13.15 (-1.25%) ▼|BMY60.47+0.31 (+0.51%) ▲|BNY158.67+1.74 (+1.11%) ▲|BRK-B489.69-1.56 (-0.32%) ▼|C132.90+4.18 (+3.25%) ▲|CAT889.71+25.41 (+2.94%) ▲|CL90.08-1.86 (-2.02%) ▼|CMCSA23.78-0.01 (-0.02%) ▼|COF206.12-0.65 (-0.31%) ▼|COP117.06+1.38 (+1.19%) ▲|COST931.02-4.78 (-0.51%) ▼|CRM170.24-3.55 (-2.04%) ▼|CSCO111.37+0.67 (+0.61%) ▲|CVS109.60+1.99 (+1.85%) ▲|CVX189.98+0.27 (+0.14%) ▲|DE589.47+3.47 (+0.59%) ▲|DHR178.69-22.42 (-11.15%) ▼|DIS96.50+0.09 (+0.09%) ▲|DUK125.59-0.26 (-0.21%) ▼|EMR139.43+2.85 (+2.09%) ▲|FDX314.80+8.58 (+2.80%) ▲|GD369.90-0.70 (-0.19%) ▼|GE340.98-0.33 (-0.10%) ▼|GEV1,083.23+4.05 (+0.38%) ▲|GILD129.80-3.41 (-2.56%) ▼|GM79.64+3.84 (+5.07%) ▲|GOOG348.19-3.18 (-0.91%) ▼|GOOGL348.89-3.10 (-0.88%) ▼|GS1,082.40+27.37 (+2.59%) ▲|HD330.63-2.41 (-0.72%) ▼|HON230.23+4.05 (+1.79%) ▲|IBM211.29-1.71 (-0.80%) ▼|INTC105.07+8.01 (+8.25%) ▲|INTU290.07-3.76 (-1.28%) ▼|ISRG357.26+4.09 (+1.16%) ▲|JNJ249.27+0.45 (+0.18%) ▲|JPM344.88+6.01 (+1.77%) ▲|KO82.09-0.04 (-0.04%) ▼|LIN506.73-5.32 (-1.04%) ▼|LLY1,163.31+16.41 (+1.43%) ▲|LMT505.40-4.14 (-0.81%) ▼|LOW203.42-1.29 (-0.63%) ▼|LRCX320.97+14.21 (+4.63%) ▲|MA538.78-8.66 (-1.58%) ▼|MCD265.19-2.45 (-0.92%) ▼|MDLZ59.79-0.49 (-0.80%) ▼|MDT82.31-0.98 (-1.18%) ▼|META647.02+1.17 (+0.18%) ▲|MMM169.90+10.79 (+6.78%) ▲|MO73.31-1.36 (-1.81%) ▼|MRK125.69+1.29 (+1.04%) ▲|MS215.36+4.42 (+2.10%) ▲|MSFT398.61-3.68 (-0.91%) ▼|MU974.66+109.20 (+12.62%) ▲|NEE87.92-0.08 (-0.09%) ▼|NFLX67.46-0.15 (-0.21%) ▼|NKE43.11-0.37 (-0.84%) ▼|NOW101.47-3.24 (-3.09%) ▼|NVDA206.09+2.81 (+1.38%) ▲|ORCL126.60+5.22 (+4.30%) ▲|PEP134.75-0.71 (-0.52%) ▼|PFE24.86+0.11 (+0.42%) ▲|PG147.65-1.49 (-1.00%) ▼|PLTR132.86-1.99 (-1.48%) ▼|PM189.68-3.04 (-1.58%) ▼|QCOM172.97+2.65 (+1.55%) ▲|RTX194.98+0.54 (+0.28%) ▲|SBUX104.48-0.33 (-0.31%) ▼|SCHW100.69-1.85 (-1.80%) ▼|SO93.68-0.78 (-0.83%) ▼|SPG226.54-1.65 (-0.72%) ▼|T22.09+0.14 (+0.62%) ▲|TMO523.98-2.25 (-0.43%) ▼|TMUS191.72-3.92 (-2.00%) ▼|TSLA380.14+10.57 (+2.86%) ▲|TXN293.49+9.42 (+3.32%) ▲|UBER71.53-0.65 (-0.89%) ▼|UNH434.26+12.71 (+3.02%) ▲|UNP294.41-1.85 (-0.62%) ▼|UPS115.91+2.76 (+2.43%) ▲|USB63.35+0.21 (+0.32%) ▲|V356.82-3.76 (-1.04%) ▼|VZ43.47-0.03 (-0.07%) ▼|WFC87.96+1.63 (+1.89%) ▲|WMT110.46-1.74 (-1.55%) ▼|XOM150.90+2.54 (+1.71%) ▲|AAPL327.36+0.77 (+0.23%) ▲|ABBV255.33+1.95 (+0.77%) ▲|ABT100.05-1.61 (-1.58%) ▼|ACN140.89-3.84 (-2.65%) ▼|ADBE226.71-8.03 (-3.42%) ▼|AMAT567.75+42.05 (+8.00%) ▲|AMD541.70+38.13 (+7.57%) ▲|AMGN364.49+0.32 (+0.09%) ▲|AMT163.75-3.32 (-1.98%) ▼|AMZN248.49-1.51 (-0.60%) ▼|AVGO386.17+8.01 (+2.12%) ▲|AXP351.03-0.90 (-0.26%) ▼|BA204.31-5.18 (-2.47%) ▼|BAC61.30+0.88 (+1.45%) ▲|BKNG177.97-1.48 (-0.82%) ▼|BLK1,040.96-13.15 (-1.25%) ▼|BMY60.47+0.31 (+0.51%) ▲|BNY158.67+1.74 (+1.11%) ▲|BRK-B489.69-1.56 (-0.32%) ▼|C132.90+4.18 (+3.25%) ▲|CAT889.71+25.41 (+2.94%) ▲|CL90.08-1.86 (-2.02%) ▼|CMCSA23.78-0.01 (-0.02%) ▼|COF206.12-0.65 (-0.31%) ▼|COP117.06+1.38 (+1.19%) ▲|COST931.02-4.78 (-0.51%) ▼|CRM170.24-3.55 (-2.04%) ▼|CSCO111.37+0.67 (+0.61%) ▲|CVS109.60+1.99 (+1.85%) ▲|CVX189.98+0.27 (+0.14%) ▲|DE589.47+3.47 (+0.59%) ▲|DHR178.69-22.42 (-11.15%) ▼|DIS96.50+0.09 (+0.09%) ▲|DUK125.59-0.26 (-0.21%) ▼|EMR139.43+2.85 (+2.09%) ▲|FDX314.80+8.58 (+2.80%) ▲|GD369.90-0.70 (-0.19%) ▼|GE340.98-0.33 (-0.10%) ▼|GEV1,083.23+4.05 (+0.38%) ▲|GILD129.80-3.41 (-2.56%) ▼|GM79.64+3.84 (+5.07%) ▲|GOOG348.19-3.18 (-0.91%) ▼|GOOGL348.89-3.10 (-0.88%) ▼|GS1,082.40+27.37 (+2.59%) ▲|HD330.63-2.41 (-0.72%) ▼|HON230.23+4.05 (+1.79%) ▲|IBM211.29-1.71 (-0.80%) ▼|INTC105.07+8.01 (+8.25%) ▲|INTU290.07-3.76 (-1.28%) ▼|ISRG357.26+4.09 (+1.16%) ▲|JNJ249.27+0.45 (+0.18%) ▲|JPM344.88+6.01 (+1.77%) ▲|KO82.09-0.04 (-0.04%) ▼|LIN506.73-5.32 (-1.04%) ▼|LLY1,163.31+16.41 (+1.43%) ▲|LMT505.40-4.14 (-0.81%) ▼|LOW203.42-1.29 (-0.63%) ▼|LRCX320.97+14.21 (+4.63%) ▲|MA538.78-8.66 (-1.58%) ▼|MCD265.19-2.45 (-0.92%) ▼|MDLZ59.79-0.49 (-0.80%) ▼|MDT82.31-0.98 (-1.18%) ▼|META647.02+1.17 (+0.18%) ▲|MMM169.90+10.79 (+6.78%) ▲|MO73.31-1.36 (-1.81%) ▼|MRK125.69+1.29 (+1.04%) ▲|MS215.36+4.42 (+2.10%) ▲|MSFT398.61-3.68 (-0.91%) ▼|MU974.66+109.20 (+12.62%) ▲|NEE87.92-0.08 (-0.09%) ▼|NFLX67.46-0.15 (-0.21%) ▼|NKE43.11-0.37 (-0.84%) ▼|NOW101.47-3.24 (-3.09%) ▼|NVDA206.09+2.81 (+1.38%) ▲|ORCL126.60+5.22 (+4.30%) ▲|PEP134.75-0.71 (-0.52%) ▼|PFE24.86+0.11 (+0.42%) ▲|PG147.65-1.49 (-1.00%) ▼|PLTR132.86-1.99 (-1.48%) ▼|PM189.68-3.04 (-1.58%) ▼|QCOM172.97+2.65 (+1.55%) ▲|RTX194.98+0.54 (+0.28%) ▲|SBUX104.48-0.33 (-0.31%) ▼|SCHW100.69-1.85 (-1.80%) ▼|SO93.68-0.78 (-0.83%) ▼|SPG226.54-1.65 (-0.72%) ▼|T22.09+0.14 (+0.62%) ▲|TMO523.98-2.25 (-0.43%) ▼|TMUS191.72-3.92 (-2.00%) ▼|TSLA380.14+10.57 (+2.86%) ▲|TXN293.49+9.42 (+3.32%) ▲|UBER71.53-0.65 (-0.89%) ▼|UNH434.26+12.71 (+3.02%) ▲|UNP294.41-1.85 (-0.62%) ▼|UPS115.91+2.76 (+2.43%) ▲|USB63.35+0.21 (+0.32%) ▲|V356.82-3.76 (-1.04%) ▼|VZ43.47-0.03 (-0.07%) ▼|WFC87.96+1.63 (+1.89%) ▲|WMT110.46-1.74 (-1.55%) ▼|XOM150.90+2.54 (+1.71%) ▲|
27.4 C
New York
Tuesday, July 21, 2026

Tag: kidney function

newssourceFORcompanyinformationcontent1releasesmarket

Phase 3 Data Show TransCon® PTH Replicated Systemic Actions of Endogenous PTH Through Week 182 in Adults with Hypoparathyroidism

COPENHAGEN, Denmark, June 13, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced Week 182 data from its completed Phase 3 PaTHway Trial showing that long-term treatment with TransCon PTH (palopegteriparatide) demonstrated sustained efficacy and safety in adults with hypoparathyroidism. Over the three-and-a-half-year duration of the trial, TransCon PTH replicated the systemic actions of endogenous PTH, with a balanced, beneficial impact on the main target organ systems – CNS, kidney, small intestine, and bone – as demonstrated by improved quality of life and normalized and stable urine calcium, serum calcium, serum phosphate, and bone mineral density. These benefits were sustained while enabling independence from conventional therapy with active vitamin D and calcium.

PureHealth Research Utilizes Bioavailable Cranberry and Astragalus in Premium Natural Supplements for Kidney Health

MANASSAS, Va., June 13, 2026 /PRNewswire/ -- PureHealth Research today addressed the growing demand for proactive kidney wellness with its collection of science-backed renal...

MBX Biosciences Announces One-Year Data Demonstrating Sustained Benefit of Once-Weekly Canvuparatide as a Potential PTH Replacement Therapy in Chronic Hypoparathyroidism

Responder rate of 57% at one year in open-label extension (OLE) comparable to 63% at 12 weeks in Phase 2 Avail™ trial

Vivoryon Therapeutics N.V. Reports Q1 2026 Financial Results and Provides Business Update

Vivoryon Therapeutics N.V. Reports Q1 2026 Financial Results
and Provides Business Update

Age is just a Number. Mobility is a Choice.

Robotics at Zydus Hospitals, Gujarat are revolutionising Joint Replacement Surgeries in the ElderlyAHMEDABAD, India, June 11, 2026 /PRNewswire/ -- Osteoarthritis and chronic joint degeneration affect...

National Kidney Foundation and U.S. Pharmacy Organizations Call for Transition to Race-Agnostic eGFR in Medication Decision-Making

NEW YORK, June 8, 2026 /PRNewswire/ -- A coalition of leading U.S. pharmacy organizations, in collaboration with the National Kidney Foundation (NKF), is urging...

Gujarat becomes the New Hub in Organ Transplantation

Zydus Hospitals Ahmedabad and Vadodara reach new heights in advanced transplant care AHMEDABAD, India, June 4, 2026 /PRNewswire/ -- Organ transplantation in India has come a...

Everest Medicines Announces Full Approval of NEFECON® in Taiwan

SHANGHAI, Aug. 6, 2025 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing,...

FDA Approves Apellis’ EMPAVELI® (pegcetacoplan) as the First C3G and Primary IC-MPGN Treatment for Patients 12 and Older

WALTHAM, Mass., July 28, 2025 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that the U.S. Food and Drug Administration (FDA) has approved EMPAVELI® (pegcetacoplan) as the first treatment for C3 glomerulopathy (C3G) or primary immune complex membranoproliferative glomerulonephritis (IC-MPGN) in patients 12 years of age and older, to reduce proteinuria. C3G and primary IC-MPGN are rare kidney diseases, affecting 5,000 people in the United States.1

PepGen Inc. Investors: Please contact the Portnoy Law Firm to recover your losses. August 8, 2025 Deadline to file Lead Plaintiff Motion.

Investors can contact the law firm at no cost to learn more about recovering their losses

Glacier Fresh Launches Prime Day 2025 Health Campaign, calls to Prioritize Clean Water Over Gadgets

New York, NY, July 08, 2025 (GLOBE NEWSWIRE) -- As Prime Day kicks off a nationwide shopping surge, Glacier Fresh is steering attention away from flash sales on electronics and toward a growing health and sustainability priority: safe, clean drinking water. Amid heightened awareness of water contamination and microplastic exposure, the company is launching its “Prime Your Hydration” campaign—urging consumers to rethink what’s coming out of their faucets and take advantage of deep discounts on its top-rated filtration systems.

Native Hydrate Variety Pack Delivers Sugar-Free Hydration with Full Electrolyte Profile and Nine Essential Amino Acids

Clean-label hydration meets real-world functionality in NativePath’s new stick pack assortment featuring natural flavors, third-party tested ingredients, and a complete hydration matrix designed for daily wellness. 
Clean-label hydration meets real-world functionality in NativePath’s new stick pack assortment featuring natural flavors, third-party tested ingredients, and a complete hydration matrix designed for daily wellness.

SeaStar Medical Announces Positive Nasdaq Listing Determination

DENVER, July 02, 2025 (GLOBE NEWSWIRE) -- Medical Holding Corporation (Nasdaq: ICU), a commercial-stage healthcare company focused on transforming treatments for critically ill patients facing organ failure and potential loss of life, announced today that it has received confirmation from The Nasdaq Stock Market that the Company has evidenced compliance with the minimum $2.5 million stockholders’ equity requirement and all other applicable criteria for continued listing on The Nasdaq Capital Market. Accordingly, the previously disclosed listing matter has been closed.

OXLUMO® (lumasiran injection) Now Reimbursed in Canada For the Treatment of Primary Hyperoxaluria Type 1 (PH1) in Pediatric and Adult Patients

OXLUMO has been shown to significantly reduce urinary oxalate, which drives the progression of PH1 Disease1 MISSISSAUGA, ON, July 2, 2025 /CNW/ - Alnylam Canada ULC...

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsKidney function

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers